PTX-200 Phase 1b/2 Clinical Update Trial

26th August 2015, ASX Announcement

• Novel cancer drug PTX-200 shows evidence of safety and antitumor activity when combined with weekly paclitaxel in advanced cancer patients
• Expansion Phase enrollment to shortly commence at Montefiore Medical Center
• Moffitt Cancer Center will now join the study under lead investigator Dr Heather Han

Clinical stage oncology company Prescient Therapeutics (ASX: PTX), today announced encouragingly early clinical data arising from their ongoing Phase 1b/2 clinical study of novel cancer drug PTX-200 trial in breast, lung and esophageal cancer.

The study is currently being conducted as an Investigator Sponsored Trial (IST) under the lead of Professor Joseph Sparano, Professor of Medicine & Obstetrics, Gynecology, and Women’s Health at Montefiore Medical Center and the Albert Einstein College of Medecine and Cancer Center, and has been partially funded by the U.S. National Cancer Institute.

Professor Joseph Sparano said PTX-200 was a highly promising oncology compound and prior studies had yet to fully exploit its potential anticancer activity “In phase 2 study that will begin upon completion of the expansion cohort, we will determine the pathologic complete response rate after PTX200 plus paclitaxel therapy in patients with locally advanced breast cancer- this model has been used in other trials to identify promising new agents and advance their development in a rapid and efficient manner.”

To read the full announcement, please click here.